Carboplatin and Paclitaxel in Patients With Metastatic, Castrate-Resistant Prostate Cancer
Status:
Terminated
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to look at the clinical benefit of carboplatin and paclitaxel
and correlate response to study treatment with biologic parameters (i.e. lab studies of
blood, urine, or tissue). It is hoped that this will allow researchers to gain insight into
the underlying biology of prostate tumor progression and perhaps predict which patients may
benefit from this chemotherapy regimen.